GLAND PHARMA
Quarterly Results Analysis [Dec2023]
GLAND PHARMA Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 Audited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,545 Cr | ₹1,373 Cr | ₹1,209 Cr | ₹785 Cr | ₹938 Cr | ₹1,044 Cr | ₹857 Cr | ₹1,103 Cr |
Expenses | ₹1,189 Cr | ₹1,049 Cr | ₹915 Cr | ₹617 Cr | ₹649 Cr | ₹748 Cr | ₹587 Cr | ₹755 Cr |
Operating Income | ₹356 Cr | ₹324 Cr | ₹294 Cr | ₹168 Cr | ₹290 Cr | ₹297 Cr | ₹270 Cr | ₹348 Cr |
Other Income | ₹37 Cr | ₹53 Cr | ₹38 Cr | ₹39 Cr | ₹62 Cr | ₹66 Cr | ₹74 Cr | ₹65 Cr |
Interest | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
Depreciation | ₹105 Cr | ₹81 Cr | ₹65 Cr | ₹38 Cr | ₹38 Cr | ₹37 Cr | ₹35 Cr | ₹31 Cr |
Profit Before Tax | ₹283 Cr | ₹290 Cr | ₹261 Cr | ₹111 Cr | ₹311 Cr | ₹324 Cr | ₹308 Cr | ₹380 Cr |
Profit After Tax | ₹192 Cr | ₹194 Cr | ₹194 Cr | ₹79 Cr | ₹232 Cr | ₹241 Cr | ₹229 Cr | ₹286 Cr |
EPS | ₹11.65 | ₹11.78 | ₹11.79 | ₹4.78 | ₹14.08 | ₹14.65 | ₹13.92 | ₹17.40 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAND PHARMA | -2.7% | -3.7% | 32.7% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
MANKIND PHARMA | 1.3% | 7% | NA |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
GLAND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 12.50 % |
Y-o-Y | 64.68 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹1,545 Cr | 12.50 | |
Sep2023 | ₹1,373 Cr | 13.63 | |
Jun2023 | ₹1,209 Cr | 53.97 | |
Mar2023 | ₹785 Cr | -16.34 | |
Dec2022 | ₹938 Cr | -10.16 | |
Sep2022 | ₹1,044 Cr | 21.88 | |
Jun2022 | ₹857 Cr | -22.31 | |
Mar2022 | ₹1,103 Cr | - |
GLAND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 9.97 % |
Y-o-Y | 23.07 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹356 Cr | 9.97 | |
Sep2023 | ₹324 Cr | 10.25 | |
Jun2023 | ₹294 Cr | 74.54 | |
Mar2023 | ₹168 Cr | -41.84 | |
Dec2022 | ₹290 Cr | -2.45 | |
Sep2022 | ₹297 Cr | 9.98 | |
Jun2022 | ₹270 Cr | -22.52 | |
Mar2022 | ₹348 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -2.29 % |
Y-o-Y | -25.28 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 23.06% | -2.29 | |
Sep2023 | 23.6% | -2.96 | |
Jun2023 | 24.32% | 13.38 | |
Mar2023 | 21.45% | -30.49 | |
Dec2022 | 30.86% | 8.59 | |
Sep2022 | 28.42% | -9.78 | |
Jun2022 | 31.5% | -0.25 | |
Mar2022 | 31.58% | - |
GLAND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -1.15 % |
Y-o-Y | -17.29 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹192 Cr | -1.15 | |
Sep2023 | ₹194 Cr | -0.01 | |
Jun2023 | ₹194 Cr | 146.69 | |
Mar2023 | ₹79 Cr | -66.08 | |
Dec2022 | ₹232 Cr | -3.85 | |
Sep2022 | ₹241 Cr | 5.27 | |
Jun2022 | ₹229 Cr | -19.84 | |
Mar2022 | ₹286 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -12.10 % |
Y-o-Y | -49.76 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 12.42 % | -12.10 | |
Sep2023 | 14.13 % | -12.02 | |
Jun2023 | 16.06 % | 60.28 | |
Mar2023 | 10.02 % | -59.47 | |
Dec2022 | 24.72 % | 7.01 | |
Sep2022 | 23.1 % | -13.61 | |
Jun2022 | 26.74 % | 3.16 | |
Mar2022 | 25.92 % | - |
GLAND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -1.10 % |
Y-o-Y | -17.26 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹11.65 | -1.10 | |
Sep2023 | ₹11.78 | -0.08 | |
Jun2023 | ₹11.79 | 146.65 | |
Mar2023 | ₹4.78 | -66.05 | |
Dec2022 | ₹14.08 | -3.89 | |
Sep2022 | ₹14.65 | 5.24 | |
Jun2022 | ₹13.92 | -20.00 | |
Mar2022 | ₹17.4 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD